Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients

Acta Haematologica

Volumn 123, Issue 4, 2010, Pages 230-234

  Palladino, Mariangela ^a   Laurenti, Luca ^a   Chiusolo, Patrizia ^a   Piccioni, Paola ^a   Innocenti, Idanna ^a   Tarnani, Michela ^a   Sorà, Federica ^a   Sica, Simona ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cytomegalovirus infection; Stem cell transplantation; Valganciclovir

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IDARUBICIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; APLASTIC ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; REDUCED INTENSITY CONDITIONING; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 77951239002     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313639     Document Type: Article

References (20)

1. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
2. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV: Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85-90.
3. Segarra-Newnham M, Salazar MI: Valganciclovir: a new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals. Pharmacotherapy 2002; 2: 1124-1128.
4. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ; Valganciclovir Study Group: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
5. Devyatko E, Zuckermann A, Ruzicka M, Bohdjalian A, Wieselthaler G, Rödler S, Wolner E, Grimm M: Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 2004; 23: 1277-1282.
6. Cvetković RS, Wellington K: Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65: 859-878.
7. Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F: Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006; 107: 3002-3008.
8. van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF: Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37: 693-698.
9. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields KK, Goldstein S: Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 851-856.
10. Meijer E, Boland GJ, Verdonck LF: Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003; 16: 647-657.
11. Candoni A, Simeone E, Tiribelli M, Pipan C, Fanin R: What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT? Bone Marrow Transplant 2008; 42: 207-208.
12. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, Ward K; European Group for Blood and Marrow Transplantation: Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33: 1075-1081.
13. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R: Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985. (Pubitemid 34525478)
14. Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B: Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29: 903-906.
15. Jiwa NM, Van Gemert GW, Raap AK, Van de Rijke FM, Mulder A, Lens PF, Salimans MM, Zwaan FE, Van Dorp W, Van der Ploeg M: Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 1989; 8: 72-76.
16. Bai X, Hosler G, Rogers BB, Dawson DB, Scheuermann RH: Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorder. Clin Chem 1997; 43: 1843-1849.
17. Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, Tarnani M, Fadda G, Sica S, Leone G: Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004; 89: 1248-1252.
18. Winston DJ, Baden LR, Gabriel DA, Emmanouilides C, Shaw LM, Lange WR, Ratanatharathorn V: Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versushost disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2006; 12: 635-640.
19. Keven K, Basu A, Tan HP, Thai N, Khan A, Marcos A, Starzl TE, Shapiro R: Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36: 3107-3112.
20. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK: Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323-1330.